Boston, United States
Research view
Switch to patient viewChronic kidney disease: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target to see only the groups that work on it.
- All targets
- SGLT2 24
- GLP-1 8
- NLRP3 0
- NRF2 1
- PI3K 0
- APOL1 3
- AKT 0
- STAT3 1
- mTOR 1
- PPAR 0
- AMPK 0
- SIRT1 0
- HIF-1 0
- TLR4 0
- STING 0
- MAPK 0
- CTNNB1 0
- TP53 0
- ERK 0
- GPX4 0
- IL-6 3
- VEGF 0
- IL-1 1
- JAK 0
- JNK 0
- TNF 1
- DPP-4 0
- EGFR 0
- YAP 0
- FGFR 0
- PCSK9 0
- APOE 0
- PINK1 0
- TFEB 0
- BCMA 3
- HMGB1 0
- HSP90 0
- BDNF 0
- GIP 0
- CD40 0
- CD47 0
- COX-2 0
- IL-17 1
- PKM2 0
- PSMA 0
- ABL1 0
- CCR5 0
- EZH2 0
- METTL3 0
- MMP-9 0
- PKD1 0
- PTEN 0
- SNCA 0
- ANGPTL3 0
- BCL-2 0
- CD19 1
- CD38 0
- CDK4/6 0
- CXCR4 0
- FTO 0
Seattle, United States
Ann Arbor, United States
Groningen, Netherlands
Herlev, Denmark
Stanford, United States
Boston, United States
Chicago, United States
Beijing, China
Minneapolis, United States
Nashville, United States
St Louis, United States
Al Mansurah, Egypt
Vienna, Austria
14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-ERC
Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN
Next-generation therapeutics for vascular diseases (TIE2gether)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
Formaldehyde crosslink exposure and genomic ageing (FORCE)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
5 of 52 running projects, newest first. Listed amounts together: €145.3m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
“Low number of participants”Registry text, quoted unchanged. Source
Withdrawn
Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
“Lack of funding and similar competing study being conducted in Europe.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 29
- Organoids 10
- Mendelian Randomization Analysis 78
- CRISPR-Cas Systems 5
- Gene Expression Profiling 88
- Sequence Analysis, RNA 4
- Whole Genome Sequencing 2
- Exome Sequencing 19
- Proteomics 103
- Metabolomics 91
- Mass Spectrometry 18
- Flow Cytometry 10
- Immunohistochemistry 19
- Liquid Biopsy 2
- Positron-Emission Tomography 5
- Magnetic Resonance Imaging 70
- Machine Learning 176
- Deep Learning 22
- Cohort Studies 553
- Genome-Wide Association Study 79
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.